Get an alert when OTTIMO PHARMA LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Cash

£83M

-26.2% vs 2024

Net assets

£80M

-28.8% vs 2024

Employees

20

+400% highest in 4 filed years

Profit before tax

Period ending 2025-12-31

Accounts

4-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31

Metric Trend 2022-12-312023-12-312024-12-312025-12-31 Δ vs prior
Turnover
Operating profit
Profit before tax
Net profit -£1,660,237-£35,346,914 -2,029%
Cash £2,297,472£984,841£112,899,276£83,292,725 -26.2%
Total assets less current liabilities £112,207,580£84,556,182 -24.6%
Net assets £2,188,452£980,052£112,252,660£79,891,214 -28.8%
Equity £2,188,452£980,052£112,252,660£79,891,214 -28.8%
Average employees 44420 +400%
Wages
Directors' remuneration

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show . About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2022-12-312023-12-312024-12-312025-12-31
Current ratio 81.43x8.18x

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Name history

Renamed 1 time since incorporation

  1. OTTIMO PHARMA LIMITED 2024-09-23 → present
  2. ULTRAHUMAN EIGHT LIMITED 2017-03-03 → 2024-09-23

Audit & accounting basis

Accounting basis
FRS 102
Reporting scope
Consolidated group
Auditor
Frazier & Deeter (UK Audit) LLP.
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The company is engaged in research and development activities and is reliant upon funding from it's investors to meet its operational and working capital needs. The company's forecasts and projections, taking account of expected expenditure and future investment, show that the company should be able to continue these activities within the level of its available facilities for the foreseeable future.”

Group structure

  1. OTTIMO PHARMA LIMITED · parent
    1. Ottimo Pharma (US), Inc 100% · US

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

7 active · 5 resigned

Name Role Appointed Born Nationality
AKKARAJU, Srinivas Director 2024-12-18 Mar 1968 American
CHIN, Mark David Director 2024-12-18 Jan 1982 American
DANSEY, Roger Delemere, Dr. Director 2025-03-17 Apr 1956 American
DE RUBERTIS, Francesco Director 2020-11-13 Jan 1970 Italian
EPSTEIN, David Robert Director 2024-10-07 Jul 1961 American
SABRY, James Henderson Director 2024-10-15 Dec 1958 American
THOMPSON, Peter Armstrong Director 2024-12-18 Jul 1959 American
Show 5 resigned officers
Name Role Appointed Resigned
THE CAMBRIDGE PARTNERSHIP LIMITED Corporate Secretary 2017-03-03 2017-07-28
COLEMAN, James Edward, Dr Director 2017-03-03 2024-09-28
EDWARDS, Jon Director 2017-04-06 2020-11-13
FINLAY, William James Jonathan, Dr Director 2017-03-03 2024-12-18
JOHNSON, Kevin Stuart, Dr Director 2017-04-06 2022-02-09

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Dr William James Jonathan Finlay Individual Shares 50–75%, Voting 50–75%, Appoints directors 2017-03-03 Ceased 2017-04-06
Dr James Edward Coleman Individual Shares 25–50%, Voting 25–50% 2017-03-03 Ceased 2017-04-06

Filing timeline

Last 20 of 74 total filings

Material constitutional events — rename, articles re-file, resolution

  • 2025-06-16 RESOLUTIONS Resolution
  • 2025-03-25 RESOLUTIONS Resolution
  • 2025-01-06 MA Memorandum articles
Date Type Category Description
2026-05-08 AA accounts Accounts with accounts type group PDF
2026-03-23 CS01 confirmation-statement Confirmation statement with updates PDF
2026-03-20 RP01AP01 officers Replacement filing of director appointment with name PDF
2026-02-26 CH01 officers Change person director company with change date PDF
2026-02-26 CH01 officers Change person director company with change date PDF
2026-02-26 CH01 officers Change person director company with change date PDF
2025-06-16 RESOLUTIONS resolution Resolution
2025-05-16 AAMD accounts Accounts amended with accounts type small
2025-05-13 AA accounts Accounts with accounts type group
2025-05-06 SH01 capital Capital allotment shares PDF
2025-04-24 AP01 officers Appoint person director company with name date
2025-03-25 RESOLUTIONS resolution Resolution
2025-03-04 CS01 confirmation-statement Confirmation statement with updates PDF
2025-02-26 TM01 officers Termination director company with name termination date PDF
2025-02-26 AP01 officers Appoint person director company with name date PDF
2025-02-24 AP01 officers Appoint person director company with name date PDF
2025-02-24 AP01 officers Appoint person director company with name date PDF
2025-02-24 SH01 capital Capital allotment shares PDF
2025-01-17 SH08 capital Capital name of class of shares
2025-01-06 MA incorporation Memorandum articles

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
7

last 12 months

Capital events
3

last 24 months

Officers appointed
0

last 12 months

Officers resigned
0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Official Companies House page